Related Experiment Video

Updated: May 17, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

c-KIT: potential predictive factor for the efficacy of sorafenib in metastatic renal cell carcinoma with sarcomatoid

Hai-Liang Zhang1, Yao Zhu, Xiao-Jian Qin

  • 1Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China.

Clinical Genitourinary Cancer
|October 13, 2012
PubMed
Abstract

Insights

c-KIT expression in metastatic renal cell carcinoma with sarcomatoid features predicts better response to sorafenib treatment. Patients with c-KIT positive tumors showed improved disease control and longer overall survival.

Area of Science:

  • Oncology
  • Molecular Pathology

Background:

  • Vascular endothelial growth factor-targeted therapy is standard for metastatic renal cell carcinoma.
  • Limited data exists on sarcomatoid tumor treatment with these agents.
  • Investigating c-KIT expression in sarcomatoid metastatic renal cell carcinoma is crucial.

Purpose of the Study:

  • To detect c-KIT expression in primary metastatic renal cell carcinoma with sarcomatoid features.
  • To evaluate c-KIT's predictive value for sorafenib efficacy.
  • To assess the impact of c-KIT on patient survival.

Main Methods:

  • Seventeen patients received sorafenib as second-line therapy.
  • Immunohistochemistry tested c-KIT expression in primary tumors.
  • Univariate and multivariate analyses correlated c-KIT status with treatment outcomes and survival.

Main Results:

  • c-KIT was overexpressed in 70.6% of specimens.
  • c-KIT positive patients had a higher disease control rate (75% vs 25%).
  • Median overall survival was significantly longer for c-KIT positive patients (92 vs 44 weeks).
  • Multivariate analysis identified c-KIT and metastatic organ number as independent prognostic factors.

Conclusions:

  • c-KIT may serve as a predictive biomarker for sorafenib treatment in metastatic renal cell carcinoma with sarcomatoid features.
  • Positive c-KIT expression is associated with better treatment response and prolonged survival.

More Related Videos

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane05:36

Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane

Published on: February 8, 2020

Related Concept Videos

M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...